title: The Glasgow Prognostic Score (GPS) is a novel prognostic indicator in advanced epithelial ovarian cancer: a multicenter retrospective study.
abstract: OBJECTIVE
  The Glasgow Prognostic Score (GPS), an inflammation-based prognostic score systems composed of C-reactive protein and albumin, has been reported to be predictive of survival in several types of malignancies. The prognostic significance of GPS in epithelial ovarian cancer (EOC) remains unclear. We conducted this study to assess the prognostic value of GPS in a cohort of patients with advanced EOC receiving neoadjuvant chemotherapy (NAC) followed by debulking surgery.
  
  
  METHODS
  Six hundred and seventy-two patients newly diagnosed with advanced EOC were retrospectively analyzed.
  
  
  RESULTS
  High GPS was significantly related to Eastern Cooperative Group performance status, histological type, histological grade and the size of residual tumor after the debulking surgery. In addition, patients with higher GPS at diagnosis achieved lower complete remission rates after NAC (P < 0.05) and had shorter progression-free survival (PFS; P < 0.001) and overall survival (OS; P < 0.001). Multivariate analysis showed high GPS was independent adverse predictors of PFS and OS.
  
  
  CONCLUSIONS
  Our data demonstrated that GPS at diagnosis is a powerful independent prognostic factor for advanced epithelial ovarian cancer. However, further studies are needed to prospectively validate this prognostic model and investigate the mechanisms underlying the correlation between high GPS and poor prognosis in advanced epithelial ovarian cancer.
authors: Department of Obstetrics and Gynecology, Nanfang Hospital of Southern Medical University, Guangzhou, 510515, Guangdong, People's Republic of China.
authors: Jiayu
authors: J
authors: Zhu
authors: Department of Hematological Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, Guangdong, People's Republic of China. wanghua@sysucc.org.cn.|State Key Laboratory of Oncology in South China, Guangzhou, 510060, Guangdong, People's Republic of China. wanghua@sysucc.org.cn.|Collaborative Innovation Center for Cancer Medicine, Guangzhou, 510060, Guangdong, People's Republic of China. wanghua@sysucc.org.cn.
authors: Hua
authors: H
authors: Wang
authors: State Key Laboratory of Oncology in South China, Guangzhou, 510060, Guangdong, People's Republic of China.|Collaborative Innovation Center for Cancer Medicine, Guangzhou, 510060, Guangdong, People's Republic of China.
authors: Cheng-Cheng
authors: CC
authors: Liu
authors: Department of Hematological Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, Guangdong, People's Republic of China.|State Key Laboratory of Oncology in South China, Guangzhou, 510060, Guangdong, People's Republic of China.|Collaborative Innovation Center for Cancer Medicine, Guangzhou, 510060, Guangdong, People's Republic of China.
authors: Yue
authors: Y
authors: Lu
authors: Department of Breast Oncology, SunYat-Sen University Cancer Center, Guangzhou, 510060, Guangdong, People's Republic of China. tanghl@sysucc.org.cn.|State Key Laboratory of Oncology in South China, Guangzhou, 510060, Guangdong, People's Republic of China. tanghl@sysucc.org.cn.|Collaborative Innovation Center for Cancer Medicine, Guangzhou, 510060, Guangdong, People's Republic of China. tanghl@sysucc.org.cn.
authors: Hailin
authors: H
authors: Tang
mesh_terms: D000418:Albumins / Q000378:metabolism; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002097:C-Reactive Protein / Q000378:metabolism; D016190:Carboplatin / Q000008:administration & dosage; D000077216:Carcinoma, Ovarian Epithelial; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000008:administration & dosage; D000077143:Docetaxel; D005260:Female; D006801:Humans; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D009367:Neoplasm Staging; D009375:Neoplasms, Glandular and Epithelial / Q000175:diagnosis* / Q000378:metabolism / Q000473:pathology / Q000628:therapy*; D010051:Ovarian Neoplasms / Q000175:diagnosis* / Q000378:metabolism / Q000473:pathology / Q000628:therapy*; D017239:Paclitaxel / Q000008:administration & dosage; D011379:Prognosis; D012189:Retrospective Studies; D043823:Taxoids / Q000008:administration & dosage
chemical_list: D000418:Albumins; D043823:Taxoids; D000077143:Docetaxel; D002097:C-Reactive Protein; D016190:Carboplatin; D017239:Paclitaxel; D002945:Cisplatin
keywords: Epithelial ovarian cancer; Glasgow Prognostic Score; Neoadjuvant chemotherapy; Prognosis